Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;11(4):2113-2119.
doi: 10.1002/ehf2.14785. Epub 2024 Apr 5.

The peptide neuromedin U (NMU) is elevated in NYHA II and III heart failure

Vincent Healy  1 , Therese Ruane O'Hora  1 , Farouk Markos  1
Affiliations

The peptide neuromedin U (NMU) is elevated in NYHA II and III heart failure

Vincent Healy et al. ESC Heart Fail. 2024 Aug.

Abstract

Aims: Currently, there is no reliable biomarker to detect pre-heart failure in humans. An early risk signal is an elevated left atrial pressure (LAP) and preliminary results from animal studies strongly suggest the neuropeptide neuromedin U (NMU) is released in response to this increase in LAP. However, it is unknown whether NMU is elevated in patients with heart failure. Therefore, the aim of this study was to assess if NMU levels are elevated in human cases of heart failure.

Methods and results: Twenty-four serum samples were obtained from patients in stage II and III heart failure from the Royal Papworth Hospital in Cambridge UK and tested using a selective NMU-ELISA; the data were compared with serum obtained commercially from self-declared healthy donors. NMU concentrations in serum from heart failure patients were significantly higher (P = 0.0007; unpaired Student's t-test) than control, 8.48 ± 0.67 ng/mL (mean ± SEM) versus 5.43 ± 0.46 ng/mL. There was no significant difference between NYHA stage II and III patients (P = 0.85, unpaired Student's t-test), which were 8.33 ± 0.89 ng/mL (n = 9) and 8.6 ± 0.95 ng/mL (n = 15), respectively. Only mean right atrial pressure was found to have a significant correlation with serum NMU (R = 0.81, P < 0.00001; regression analysis).

Conclusions: NMU is elevated in serum from stage II and III heart failure patients, supporting data from our pre-heart failure animal model; however, further study is needed to determine whether NMU is a reliable biomarker for pre-heart failure.

Keywords: Biomarker; Elevated left atrial pressure; Human; Pre‐heart failure.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
There is a significant correlation between mean right atrial pressure and NMU serum concentration in heart failure patients. R = 0.81, P < 0.00001 (regression).
Figure 2
Figure 2
There is no significant correlation between mean PCWP (top, R = 0.24, P = 0.27) or mean right atrial pressure (bottom, R = 0.11, P = 0.6; ANOVA) and NMU serum concentration in heart failure patients.
See this image and copyright information in PMC

References

    1. Sanchis L, Gabrielli L, Andrea R, Falces C, Duchateau N, Perez‐Villa F, et al. Left atrial dysfunction relates to symptom onset in patients with heart failure and preserved left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging 2015;16:62‐67. doi:10.1093/ehjci/jeu165 - DOI - PubMed
    1. Ritzema J, Melton IC, Richards AM, Crozier IG, Frampton C, Doughty RN, et al. Direct left atrial pressure monitoring in ambulatory heart failure patients: Initial experience with a new permanent implantable device. Circulation 2007;116:2952‐2959. doi:10.1161/CIRCULATIONAHA.107.702191 - DOI - PubMed
    1. Hasenfuss G, Gustafsson F, Kaye D, Shah SJ, Burkhoff D, Reymond MC, et al. Rationale and design of the reduce elevated left atrial pressure in patients with heart failure (reduce LAP‐HF). Trial J Card Fail 2015;21:594‐600. doi:10.1016/j.cardfail.2015.05.008 - DOI - PubMed
    1. Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, et al. Physician‐directed patient self‐management of left atrial pressure in advanced chronic heart failure. Circulation 2010;121:1086‐1095. doi:10.1161/CIRCULATIONAHA.108.800490 - DOI - PubMed
    1. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner‐La Rocca HP, et al. The use of diuretics in heart failure with congestion ‐ A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137‐155. doi:10.1002/ejhf.1369 - DOI - PubMed

LinkOut - more resources